Ray Barlow, SynOx Therapeutics CEO

Irish biotech col­lects $75M in Se­ries B to start Phase 3 rare joint tu­mor tri­al

Syn­Ox Ther­a­peu­tics has com­plet­ed a $75 mil­lion Se­ries B raise to ad­vance its mon­o­clon­al an­ti­body drug through a reg­is­tra­tional tri­al for a type of non-can­cer­ous growth.

The fundraise – co-led by For­bion and Health­Cap with new in­vestor Bio­qube Ven­tures – will sup­port the de­vel­op­ment of emac­tuzum­ab in tenosyn­ovial gi­ant cell tu­mor (TGCT).

TGCT is caused by chro­mo­so­mal ab­nor­mal­i­ties that trig­ger over­pro­duc­tion of CSF-1 pro­tein, which sup­press­es the body’s T cell-me­di­at­ed im­mune re­sponse against tu­mors. “Pa­tients have these large, in­va­sive tu­mors that dis­rupt all as­pects of their lives,” from re­strict­ed mo­bil­i­ty to con­sid­er­able pain, Syn­Ox CEO Ray Bar­low told End­points News in an in­ter­view.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.